Navigation

Press Release

Create Date: 20 April 2004

Outstanding research in depression and anxiety is granted “Freedom to Discover Award 2004” by Bristol-Myers Squibb

Neuronova founder Prof. Florian Holsboer receives award as lead researcher for the Max-Planck-Institute of Psychiatry

Munich, April 20, 2004 – Neuronova AG, a biopharmaceutical company implementing novel concepts for the treatment of depression and anxiety, announces that its founder Prof. Florian Holsboer today receives Bristol-Myers Squibb´s “Freedom to Discover Award 2004” as lead researcher for the Max-Planck-Institute of Psychiatry. The award has been granted to the institute for outstanding research in neurosciences and consists of US $500.000 distributed over five years.

The work of Prof. Holsboer and the team has revealed new insights into the mechanisms that underlie depression and anxiety and has led to a better understanding of the complex interactions involved in the development of the disease, including the role of stress hormones.

Attachments:
File	File size
2004-04 NN - BMS Award engl.pdf	66 Kb

Press Release

Create Date: 10 November 2003

LSP COMPLETES FIRST CLOSING OF €4 MILLION SERIES A INVESTMENT IN NEURONOVA AG, MUNICH

Amsterdam, Munich, November 10, 2003 – Life Sciences Partners (LSP) has today made an initial commitment to NeuroNova AG in Munich, Germany, as part of a €4 million round of equity financing.

NeuroNova is a bio-pharmaceutical company in the field of affective disorders. Its main founder, Prof. Florian Holsboer, is the Director of the Max-Planck-Institute for Psychiatry in Munich which he has established during the past decade as one of the world leading centers in the research and clinical development of therapies for psychiatric disorders. Prof. Holsboer has made ground-breaking contributions to the field of depression and anxiety disorders and has paved the way for several collaborative undertakings with pharmaceutical companies in order to discover and develop better drug treatments for psychiatric disorders. Dr. Herbert Stadler, also a founder, is the former CEO of Develogen AG in Göttingen, Germany, and of other successful biotech enterprises. He will assume the role of CEO of NeuroNova going forward. Another founding shareholder is the Max-Planck-Society, in recognition of its important contributions to NeuroNova AG and its continued support of this exciting new company.

Attachments:
File	File size
Press Release Neuronova 03-11.pdf	699 Kb